echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Paclitaxel liposome was selected as the preferred combination drug for multiple radiotherapy and chemotherapy in the new edition of "Chinese Guidelines for Radiation Therapy of Esophageal Cancer"

    Paclitaxel liposome was selected as the preferred combination drug for multiple radiotherapy and chemotherapy in the new edition of "Chinese Guidelines for Radiation Therapy of Esophageal Cancer"

    • Last Update: 2022-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Esophageal cancer is a high-incidence malignant tumor, ranking 7th and 6th in global morbidity and mortality, respectively, causing about 450,000 deaths each year
    .
    China has the highest incidence of esophageal cancer in the world, accounting for more than half of the world's total incidence
    .
    In recent years, a series of gratifying new progress has been made in the field of esophageal cancer treatment in China
    .
    1.
    Guidelines for esophageal cancer radiotherapy for Chinese patients released Esophageal cancer mainly includes esophageal adenocarcinoma (OAC) and esophageal squamous cell carcinoma (SCC)
    .
    Esophageal squamous cell carcinoma has strong histological and biological characteristics, including multi-regional lymph node metastasis, obvious local invasion, and variable onset location.
    It has obvious geographical aggregation in China
    .
    The early symptoms of esophageal cancer are generally not obvious, and most patients are often diagnosed in the middle and late stages
    .
    Different from the common esophageal adenocarcinoma in Europe and the United States, more than 90% of esophageal cancers in China are esophageal squamous cell carcinoma
    .
    In order to meet the clinical practice in China, the Radiation Oncology Physicians Branch of the Chinese Medical Doctor Association / the Radiation Oncology Branch of the Chinese Medical Association / the Professional Committee of Radiation Oncology of the China Anti-Cancer Association jointly formulated the "Guidelines for Radiation Therapy of Esophageal Cancer in China" in 2019.
    The formulation of this guideline fills the gap of guidelines in the field of radiation therapy for esophageal cancer in China
    .
    Recently, the 2021 edition of "Guidelines for Radiation Therapy of Esophageal Cancer in China" has been released based on the clinical application recommendations and the latest research results in the past two years.
    2.
    Radiotherapy is an important means of comprehensive treatment of esophageal cancer.
    Surgery, radiotherapy, interventional therapy, chemotherapy, traditional Chinese medicine, etc.
    can be selected, among which radiotherapy plays an important role in the comprehensive treatment of esophageal cancer
    .
    According to guideline recommendations, for operable esophageal cancer, neoadjuvant chemoradiotherapy followed by surgery is the standard treatment; for inoperable esophageal cancer, concurrent chemoradiotherapy is the only radical plan; postoperative adjuvant radiotherapy can improve the local control rate and survival of some patients.
    rate
    .
    The optimal regimen combined with chemoradiotherapy including chemotherapy, targeted therapy or immunotherapy and radiosensitizers still needs further study
    .
    3.
    Paclitaxel liposome and glycidazole sodium continue to be recommended by the "Guidelines" It is worth noting that after Luye Pharma's paclitaxel liposome and glycidazole sodium were both included in the 2019 edition of the "Chinese Guidelines for Radiation Therapy of Esophageal Cancer" , was again included in the "Chinese Guidelines for Radiation Therapy of Esophageal Cancer (2021 Edition)", and paclitaxel liposome was selected as the preferred combination drug for multiple radiotherapy and chemotherapy
    .
    Paclitaxel is one of the commonly used chemotherapeutic drugs for esophageal cancer.
    It has both strong cytotoxicity and radiosensitization effect
    .
    The so-called radiosensitizer is a chemical or pharmaceutical preparation that can selectively enhance the killing effect of radiation on tumor cells without affecting normal tissue cells, thereby improving the control rate and cure rate of tumors
    .
    Glycidazole sodium, also known as "Chinese Miso" (Chinese imidazole, CMNa for short), is the first high-efficiency and low-toxicity chemoradiotherapy sensitizer officially used in clinical practice at home and abroad
    .
    This is also a national first-class anticancer drug developed in China with independent intellectual property rights
    .
    The latest revision of the 2021 edition of the "Chinese Guidelines for Radiation Therapy of Esophageal Cancer" further pointed out that paclitaxel can be used for neoadjuvant chemotherapy (limited to esophageal adenocarcinoma)/neoadjuvant chemoradiotherapy, radical chemoradiotherapy, postoperative chemotherapy/radiochemotherapy and palliative in sexual chemotherapy
    .
    In addition, in the commonly used chemotherapy regimens for esophageal cancer, paclitaxel and paclitaxel liposomes are interchangeable according to disease needs or toxicity
    .
    4.
    Paclitaxel liposomes have been recommended by multiple authoritative guidelines and consensuses Paclitaxel liposomes belong to paclitaxel nano formulations, which are the first commercialized paclitaxel liposome preparations, and are currently the only paclitaxel liposome preparations on the market
    .
    The drug's unique tumor and lymph node targeting and long half-life can better exert its anti-tumor effect while achieving better safety and tolerability
    .
    In the 16 years since its launch, paclitaxel liposomes have been used by more than 2 million patients, and its good efficacy and safety have been widely recognized in long-term clinical applications
    .
    Paclitaxel liposomes have also been recommended by many authoritative guidelines and consensuses, including: Paclitaxel liposomes are included in the "CSCO Breast Cancer Diagnosis and Treatment Guidelines (2020 Edition)" as a first-line drug, "CSCO Primary Lung Cancer Diagnosis and Treatment Guidelines (2019 Edition)" )", and was included in the "Expert Consensus on the Clinical Application of Taxanes in Gynecologic Malignancies" and "Expert Consensus on the Clinical Application of Taxanes in Breast Cancer (2020)"
    .
    The publication of the "Guide" provides a standardized protocol for radiotherapy for patients with advanced esophageal cancer in China
    .
    Despite this, experts still remind that people should try to avoid eating pickled vegetables, smoking and drinking, and eating too fast, too cold, and hard food and other bad habits.
    The role of early treatment and prevention
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.